Denial of Memory Deficit in Alzheimer's Disease

1993 ◽  
Author(s):  
S. Sevush ◽  
◽  
N. Leve
Author(s):  
Luana Leão ◽  
Laís Felício ◽  
Knut Engedal ◽  
Gro Tangen ◽  
Kari Kristiansen ◽  
...  

: Elevated peripheral expression of homocysteine (Hcy) is associated with an increased risk of coronary heart disease and stroke, diabetes, and cancer. It is also associated with cognitive impairment as it has been reported that high levels of Hcy cause cognitive dysfunction and memory deficit. Among several etiological factors that contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD), Hcy seems to directly contribute to the generation of neurotoxicity factors. This study aims to hypothesize the molecular mechanism by which exercise can reduce the risk of neurological complications promoted by hyperhomocysteinemia (HHcy), and discuss how exercise could reduce the risk of developing AD by using bioinformatics network models. According to the genes network, there are connections between proteins and amino acids associated with Hcy, exercise, and AD. Studies have evidenced that exercise may be one of several processes by which nitric acid availability can be maximized in the human body, which is particularly important in reducing cell loss and tau pathology , thereby reducing in the risk of complications associated with HHcy and AD.


2014 ◽  
Vol 41 (4) ◽  
pp. 1109-1116 ◽  
Author(s):  
Jing Xie ◽  
Audrey Gabelle ◽  
Aline Dorey ◽  
Antoine Garnier-Crussard ◽  
Armand Perret-Liaudet ◽  
...  

2012 ◽  
Vol 8 (4S_Part_15) ◽  
pp. P552-P552
Author(s):  
Aline Dorey ◽  
Armand Perret-Liaudet ◽  
Floriane Delphin-Combe ◽  
Bernadette Mercier ◽  
Isabelle Roullet-Solignac ◽  
...  

2010 ◽  
Vol 391 (8) ◽  
Author(s):  
Vivian Hook ◽  
Gregory Hook ◽  
Mark Kindy

Abstract Beta-amyloid (Aβ) in the brain is a major factor involved in Alzheimer's disease (AD) that results in severe memory deficit. Our recent studies demonstrate pharmacogenetic differences in the effects of inhibitors of cathepsin B to improve memory and reduce Aβ in different mouse models of AD. The inhibitors improve memory and reduce brain Aβ in mice expressing the wild-type (WT) β-secretase site of human APP, expressed in most AD patients. However, these inhibitors have no effect in mice expressing the rare Swedish (Swe) mutant amyloid precursor protein (APP). Knockout of the cathepsin B decreased brain Aβ in mice expressing WT APP, validating cathepsin B as the target. The specificity of cathepsin B to cleave the WT β-secretase site, but not the Swe mutant site, of APP for Aβ production explains the distinct inhibitor responses in the different AD mouse models. In contrast to cathepsin B, the BACE1 β-secretase prefers to cleave the Swe mutant site. Discussion of BACE1 data in the field indicate that they do not preclude cathepsin B as also being a β-secretase. Cathepsin B and BACE1 could participate jointly as β-secretases. Significantly, the majority of AD patients express WT APP and, therefore, inhibitors of cathepsin B represent candidate drugs for AD.


2022 ◽  
Author(s):  
Mengmeng You ◽  
Kangli Wang ◽  
Yongming Pan ◽  
Lingchen Tao ◽  
Quan-xin Ma ◽  
...  

Alzheimer’s disease (AD), the most common form of neurodegenerative dementia among the older population, is associated with acute or chronic inflammation. As a nonsteroidal anti-inflammatory drug, aspirin has recently been...


Sign in / Sign up

Export Citation Format

Share Document